Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Investing.com - Piper Sandler has reduced its price target on Karyopharm Therapeutics (NASDAQ:KPTI) to $12.00 from $15.00 while maintaining an Overweight rating on the stock following the company’s financial restructuring. According to InvestingPro data, the company appears undervalued despite facing significant operational challenges, with analyst targets ranging from $6.00 to $67.50.
The research firm noted that Karyopharm has completed a multipart financial restructuring that will fund operations into the second quarter of 2026, extending through the expected Phase III SENTRY trial data in myelofibrosis anticipated in March.
Piper Sandler estimates that Karyopharm now holds approximately $82 million in pro forma cash with $231 million in debt. The company has 15.9 million shares outstanding, along with 2.9 million pre-funded warrants and 9.0 million warrants with a $6.64 strike price.
For the third quarter of 2025, Karyopharm reported XPOVIO net revenues of approximately $32 million and total revenues between $42-44 million.
The investment firm remains positive on Karyopharm’s prospects ahead of the Phase III SENTRY data expected in March, as well as the Phase III XPORT-EC-042 trial results on selinexor maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer patients anticipated in mid-2026.
In other recent news, Karyopharm Therapeutics reported a decline in revenue for the second quarter of 2025, with total revenue dropping to $37.9 million from $42.8 million in the previous year. Despite the overall revenue decline, the company noted a 6% year-over-year increase in net product revenue for its flagship product, XPOVIO. Karyopharm has secured financing transactions expected to provide $100 million in financial flexibility and additional capital, extending its cash runway into the second quarter of 2026. These transactions include $67.5 million through new term loans, convertible notes, and payment deferrals, along with a reduction in minimum liquidity requirements. Additionally, the company completed enrollment in its Phase 3 SENTRY trial for myelofibrosis, with top-line results anticipated in March 2026. In analyst updates, Leerink Partners lowered its price target for Karyopharm to $6.00 from $8.00 while maintaining a Market Perform rating. The financing deal, which includes $27.5 million in new term loan borrowings and convertible notes, is expected to close around October 10. Holders of approximately $24.25 million of the company’s senior unsecured convertible notes have agreed to exchange their notes for newly issued common stock or pre-funded warrants.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.